Product Center
Influenza Virus Subunit Vaccine Application Accepted!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-06-07
- Views:
(Summary description)On June 7, 2024, Ab&B Bio-Tech Co., Ltd. (JS) (hereinafter referred to as "Ab&B Bio") announced that the application for its "Influenza Virus Subunit Vaccine" was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People's Republic of China.
Influenza Virus Subunit Vaccine Application Accepted!
(Summary description)On June 7, 2024, Ab&B Bio-Tech Co., Ltd. (JS) (hereinafter referred to as "Ab&B Bio") announced that the application for its "Influenza Virus Subunit Vaccine" was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People's Republic of China.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-06-07 14:01
- Views:
On June 7, 2024, Ab&B Bio-Tech Co., Ltd. (JS) (hereinafter referred to as "Ab&B Bio") announced that the application for its "Influenza Virus Subunit Vaccine" was accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of the People's Republic of China.
Source: Official Website of the Center for Drug Evaluation, NMPA
At present, the influenza virus remains one of the most important respiratory pathogens threatening public health. Seasonal influenza outbreaks or occasional cross-species transmission of influenza viruses and pandemics have significant impacts on human health and socioeconomic development. The WHO position paper on influenza vaccination and the Chinese CDC's Technical Guidelines for Influenza Vaccination in China (2023-2024) clearly state that annual influenza vaccination is the most cost-effective preventive measure, which can significantly reduce the risk of influenza and serious complications.
This year, WHO noted that since March 2020, the global influenza surveillance network has not detected the B/Yamagata virus, and therefore recommended removing the B/Yamagata lineage component from influenza vaccines. Ab&B Bio responded promptly and initiated the regulatory submission for its influenza virus subunit vaccine to accelerate product launch, thereby supporting scientific influenza prevention and control efforts and expanding vaccine options for the public.
Ab&B Bio has always focused on innovation rather than imitation, dedicating itself to subunit influenza vaccine technology. To date, Ab&B Bio's subunit influenza vaccine portfolio includes: quadrivalent influenza virus subunit vaccine for individuals aged 6-35 months, quadrivalent influenza virus subunit vaccine for individuals aged 3 years and older, adjuvanted quadrivalent influenza virus subunit vaccine for the elderly, trivalent influenza virus subunit vaccine, adjuvanted trivalent influenza virus subunit vaccine for the elderly, as well as other subunit influenza vaccines in development. These products precisely address the needs of diverse populations. Among them, the quadrivalent influenza virus subunit vaccine (HRK-X®) for individuals aged 3 years and older has been commercially available, gaining positive feedback for its high purity, low reactogenicity, excellent safety, and broad protection. Ab&B Bio will continue to uphold innovation-driven strategies and quality leadership, aiming to launch all its influenza vaccine products expeditiously and further contribute to influenza prevention and control with cutting-edge solutions!
Relevant information
-
The Launch Meeting of Phase I/II Clinical Trial for Recombinant Herpes Zoster Vaccine (CHO Cell) was successfully heldRecently, the Phase I/II clinical trial launch meeting for the recombinant herpes zoster vaccine (CHO cell), co-developed by Ab&B Bio-Tech CO., LTD. JS. and Yither Biotech (Shanghai) Co., Ltd., was successfully held in Henan, and the first-in-human (FIH) dosing was successfully completed. - Ab&B Bio and Yither Bio Have Both Obtained Qualification Certification! 12-30
- Kickoff Meeting for Clinical Research on Quadrivalent Influenza Virus Subunit Vaccine in Children with Nephrotic Syndrome Successfully Held 12-25
- IND Application for Influenza Virus Subunit Vaccine (Adjuvanted) Approved 10-30
- The Application for the Marketing of Trivalent Influenza Virus Subunit Vaccine has been Accepted! 10-08
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
